








key: cord-294800-akr4f5p8
authors: Kabir, Md. Tanvir; Uddin, Md. Sahab; Hossain, Md. Farhad; Abdulhakim, Jawaher A.; Alam, Md. Asraful; Ashraf, Ghulam Md; Bungau, Simona G.; Bin-Jumah, May N.; Abdel-Daim, Mohamed M.; Aleya, Lotfi
title: nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics
date: 2020-07-10
journal: Front Cell Dev Biol
DOI: 10.3389/fcell.2020.00616
sha: 
doc_id: 294800
cord_uid: akr4f5p8

In December 2019, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related epidemic was first observed in Wuhan, China. In 2020, owing to the highly infectious and deadly nature of the virus, this widespread novel coronavirus disease 2019 (nCOVID-19) became a worldwide pandemic. Studies have revealed that various environmental factors including temperature, humidity, and air pollution may also affect the transmission pattern of COVID-19. Unfortunately, still, there is no specific drug that has been validated in large-scale studies to treat patients with confirmed nCOVID-19. However, remdesivir, an inhibitor of RNA-dependent RNA polymerase (RdRp), has appeared as an auspicious antiviral drug. Currently, a large-scale study on remdesivir (i.e., 200 mg on first day, then 100 mg once/day) is ongoing to evaluate its clinical efficacy to treat nCOVID-19. Good antiviral activity against SARS-CoV-2 was not observed with the use of lopinavir/ritonavir (LPV/r). Nonetheless, the combination of umifenovir and LPV/r was found to have better antiviral activity. Furthermore, a combination of hydroxychloroquine (i.e., 200 mg 3 times/day) and azithromycin (i.e., 500 mg on first day, then 250 mg/day from day 2–5) also exhibited good activity. Currently, there are also ongoing studies to evaluate the efficacy of teicoplanin and monoclonal and polyclonal antibodies against SARS-CoV-2. Thus, in this article, we have analyzed the genetic diversity and molecular pathogenesis of nCOVID-19. We also present possible therapeutic options for nCOVID-19 patients.

Coronaviruses (CoVs) belong to the large family of positivesense, enveloped, highly diverse, and single-stranded RNA viruses (Fehr and Perlman, 2015) . Indeed, CoVs have been found to infect both humans and animals, therefore causing various respiratory, gastrointestinal, neuronal, and hepatic diseases (Weiss and Leibowitz, 2011; Chan et al., 2013; Zumla et al., 2016) . Former epidemics of CoVs include severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, these outbreaks caused severe health problems in humans . A group of individuals was admitted to hospitals in late December of 2019 with a primary diagnosis of pneumonia due to an unknown cause (Bogoch et al., 2020; Lu et al., 2020) . It was assumed by the earlier reports that the onset of a potential CoV epidemic provided the estimation of a reproduction number for the 2019 novel coronavirus (nCOVID-19, named by World Health Organization (WHO) on Feb 11, 2020) which was thought to be considerably >1 (ranges from 2.24-3.58) .

This severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be transmitted largely via droplets and due to the close contact. It has been found that elderly people and individuals with chronic diseases or comorbidities are particularly high-risk populations (Li et al., 2020a) . There are various symptoms of nCOVID-19 including cough (68%), fever (88%), diarrhea (3.7%), and vomiting (5%) (Mungroo et al., 2020) . The mode of transmission of SARSCoV-2 is supposed to take place from human to human through respiratory secretions released by the infected people when sneezing and coughing (Mungroo et al., 2020) . nCOVID-19 patients can be asymptomatic, which is making the control of the transmission more difficult (Gao et al., 2020; Li et al., 2020a) . Since February of 2020, strict infection control approaches were executed by the Centers for Disease Control (CDC) in order to limit the spread of SARS-CoV-2. In a recent study, mentioned that nCOVID-19 patients had the highest viral load (measured in saliva samples) near presentation. They also summarized that as viral load is quite high during the time of hospital admissions, use of potent antiviral agents at an early stage might prove Abbreviations: ACE2, angiotensin converting enzyme 2; AP, antigen presentation; APCs, antigen presentation cells; APN, aminopeptidase N, ARBs, angiotensin II receptor blockers; ARDS, acute respiratory distress syndrome; CDC, Centers for Disease Control; nCOVID-19, novel coronavirus disease 2019; CoVs, coronaviruses; DPP4, dipeptidyl peptidase 4; dsRNA, double-strand RNA; EC 50 , half maximal effective concentration; ED, emergency department; ELISA, enzymelinked immunosorbent assay; EUA, emergency use authorization; FDA, Food and Drug Administration; GGO, ground-glass opacity; HCV, hepatitis C virus; HIV, human immunodeficiency virus;, MHC, major histocompatibility complex; or HLA, human leukocyte antigen; ICU, intensive care unit; IL-6, interleukin 6; LPV/r, lopinavir/ritonavir; mAbs, monoclonal antibodies; MERS, Middle East respiratory syndrome; N7-MTase, N7-methyltransferase; NSAIDs, nonsteroidal anti-inflammatory drugs; PRRs, pattern recognition receptors; PUI, patient under investigation; RdRp, RNA-dependent RNA polymerase; RSV, respiratory syncytial virus; S protein, spike protein; SAM, S-adenosyl-methionine; SARS, severe acute respiratory syndrome; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; TMPRSS2, transmembrane serine protease 2; WHO, World Health Organization. beneficial in managing the severity of nCOVID-19 infection .

Previously, SARS was found to be partially linked with environmental factors (Lin et al., 2006) . In a study, it was revealed that air pollution was linked with mortality in SARS patients in China (Cui et al., 2003) . In this regard, it was mentioned that lung functions can be compromised owing to long-or shortterm exposure to certain environmental pollutants (Cui et al., 2003) . Air temperature is another factor that is also needed to be considered. It has been revealed by Lin et al. (2006) that the occurrence of SARS was much higher (18 times) at lower air temperatures as compared to higher temperatures. Researchers also showed that respiratory disorders are more likely to take place in colder environments since virulence of agents are likely to deteriorate at higher air temperatures because they might not endure the alterations in the environment (D'Amato et al., 2018) . In addition to this, they also summarized that SARS-CoV's transmissibility is comparable with the transmissibility of influenza virus. Moreover, the occurrence of influenza markedly elevates with high relative humidity and low temperatures (Park et al., 2020) , which is further suggesting that viral transmission can be significantly affected by environmental factors.

There are no therapeutic agents that have been approved to treat nCOVID-19. Various medicines including immunomodulatory or antiviral drugs such as remdesivir, favipiravir, ribavirin, chloroquine, hydroxychloroquine, azithromycin, nitazoxanide, teicoplanin etc. have been advised as potential investigational drugs, many of which are now being studied in animals and humans WHO, 2020c) . On March 28, 2020, the Food and Drug Administration (FDA) gave an emergency use authorization (EUA) for emergency use of oral administrations of chloroquine phosphate and hydroxychloroquine sulfate to treat SARS-CoV-2 infection (FDA, 2020) . Along with oxygen and mechanical ventilation, a guideline has also been published by Belgium which involved recommendations from four other European countries, including Switzerland, Netherlands, France, and Italy that recommended the use of remdesivir, lopinavir/ritonavir, tocilizumab, and chloroquine or hydroxychloroquine (Sciensano, 2020) . In addition, Japan and China approved the use of favipiravir (an antiviral agent) to treat influenza, which is now under investigation to treat nCOVID-19 (Fujifilm, 2020) .

In this article, we have critically appraised the genetic diversity, molecular pathogenesis, symptoms, diagnosis, and prevention of nCOVID-19. Furthermore, we also specially reviewed the mechanisms, efficacy, and use of various drugs that might be beneficial in combating nCOVID-19 infection.

In nature, nucleotide substitution is considered as a vital step for viral evolution (Lauring and Andino, 2010) . The rapid spreading of SARS-CoV-2 raised a suspicion that mutations are driving its evolution. In a recent study, from GISAID, Phan (2020a) collected 86 complete or near-complete SARS-CoV-2 genomes to estimate its genetic variation. In addition to this, these strains of SARS-CoV-2 were identified in patients with confirmed nCOVID-19 from USA (11), China (50), Japan (5), Australia (5), England (2), Singapore (3), France (4), Germany (1), Belgium (1), South Korea (1), Vietnam (1), and Taiwan (2). ClustalX2 was used to align the pair-wise nucleotide sequence (Saitou and Nei, 1987) . As a reference genome, the sequence of the strain "China/WHU01/2020/EPI_ISL_406716" was used. Interestingly, similar to other beta coronaviruses, the genome of SARS-CoV-2 contains a long ORF1ab polyprotein at the 5 ′ end, followed by 4 main structural proteins, such as nucleocapsid protein, matrix protein, small envelope protein, and spike surface glycoprotein (Phan, 2020b) . In addition to this, it was also observed that there were 3 deletions in the genomes of SARS-CoV-2 from Australia (Victoria), USA (Wisconsin), and Japan (Aichi). In contrast, 1 deletion (10 nucleotides) was found in the 3 ′ end of the genome, while 2 deletions (2 nucleotides and 24 nucleotides) were found in the ORF1ab polyprotein. Furthermore, it was also observed from the nucleotide sequence alignment that there were 93 missense mutations in the entire genomes of novel coronavirus (Table 1) . Except for the envelope protein, 42 mutations were detected in all of the main structural and non-structural proteins. Whereas, 4 missense mutations were observed in the nucleocapsid protein, 1 in the matrix protein, 29 in the ORF1ab polyprotein, and 8 in the spike surface glycoprotein. Interestingly 3 mutations (i.e., Phe 367 , Tyr 364 , and Asp 354 ) were found in the spike surface glycoprotein receptor-binding domain. Indeed, spike surface glycoprotein contributes significantly in binding to receptors on the host cell and eventually regulates host tropism (Fung and Liu, 2019) . Furthermore, this spike glycoprotein is the main target of neutralizing antibodies . Conformational changes of spike glycoprotein can be induced by the mutations, which can lead to altered antigenicity. Up until now, no study has identified the amino acids that are involved in conformational alterations of spike glycoprotein. Therefore, further studies are required to identify these important amino acids.

Various wild and domestic animals such as bats, cats, cattle, and camels might play a role as hosts for coronaviruses (Adhikari et al., 2020) . In general, animal coronaviruses do not spread among human beings (CDC, 2020a) . Nevertheless, exceptions have been noticed in case of MERS and SARS, where these diseases were found to be transmitted owing to the contact with respiratory droplets from sneezing or coughing of nCOVID-19 patients. Initial nCOVID-19 patients were detected in China, where there was an association with the seafood market of Wuhan, which is indicating that these initial infections took place because of the animal-to-person transmission. Later on, nCOVID-19 was also detected in healthcare professionals and also in other individuals where there was no history of contact with that affected area of Wuhan, which is further suggesting the human-to-human transmission (Gralinski and Menachery, 2020; Huang et al., 2020; Li et al., 2020b; Liu et al., 2020; WHO, 2020d) .

As per the recent guidelines from health authorities of China (Adhikari et al., 2020; WHO, 2020e) , there are 3 major routes of nCOVID-19 transmission including droplets transmission, aerosol transmission, and contact transmission. Transmissions via droplets were found to take place when respiratory droplets of infected individuals are inhaled or ingested by people who are in close contact. Whereas, contact transmission might take place when a person touches a virus-contaminated-object or surface and then that person touches his/her nose, mouth, or eyes. On the other hand, aerosol transmission might take place when respiratory droplets mix into the air, thus forms aerosols and might result in infection when a high dose of aerosols are inhaled into the lungs in a comparatively closed environment (Adhikari et al., 2020; WHO, 2020e) . In a study, it was revealed that the digestive system is also a possible route for SARS-CoV-2 transmission. Symptoms like diarrhea and abdominal discomfort have been observed in individuals with confirmed nCOVID-19, this observation led to studies which revealed that ACE2 (to which SARS-CoV-2 binds) is highly expressed in enterocytes of colon and ileum .

The effect of temperature on the health of humans can be varied depending on the countries or even areas (Hajat and Kosatky, 2010) . In line with this aforesaid finding, it was also reported that temperature can affect the transmission of respiratory syndromes-causing viruses including SARS-CoV-2 (Ma et al., 2020) and influenza virus (Park et al., 2020) . Studies have also revealed that novel coronavirus and influenza virus can survive only in some specific environmental conditions and their transmissions also depend on temperatures (Chan et al., 2011; Jaakkola et al., 2014) , which is also applicable for SARS-CoV-2 transmission (Wang et al., 2020c) . It was observed in case of influenza virus that it can transmit more readily at lower temperatures (Lowen and Steel, 2014) , since host immunity is likely to remain weakened in cold weather, this can further increase the vulnerability toward infection (Kudo et al., 2019) . As the transmission process of coronaviruses is comparable with the influenza virus transmission (Lin et al., 2006) , thus it can be expected that these processes are also applicable for the SARS-CoV-2 transmission (Wang et al., 2020c) .

Several other environmental factors can affect the link between mortality and temperature including air pollution (Cai et al., 2007) , humidity (Jaakkola et al., 2014; Kudo et al., 2019) , latitude (Bao et al., 2016) . In this regard, socio-demographic factors including income, age, and gender (Bao et al., 2016) have also been reported to play roles. In a study, Chan et al. (2011) revealed that individuals who live at lower latitudes showed a strong adaptive capacity toward heat, and a relatively weak adaptive capacity was observed toward cold. These researchers also observed that the viability of SARS-CoV was much lower at higher relative humidity and higher temperatures (for example, relative humidity: over 95%, and temperature: 38 • C). In a different study, it was revealed that humidity and temperature are linked with an increased risk of nCOVID-19 (Wang et al., 2020c) . Interestingly, coronaviruses can persist on inanimate surfaces including plastic, glass, or metal for up to 9 days (Kampf et al., 2020) .

nCOVID-19 patients exhibit various clinical symptoms including cough, fever, fatigue, radiographic evidence of pneumonia, dyspnea, decreased or normal leukocyte counts, and myalgia . These aforesaid symptoms are also similar to MERS-CoV and SARS-CoV infections (Peiris et al., 2004) . Even though nCOVID-19 pathogenesis is not well-understood, however the similar mechanisms used previously by MERS-CoV and SARS-CoV can provide a lot of information regarding SARS-CoV-2 pathogenesis (Figure 1 ).

Spike protein (S protein) of coronavirus determines the viral entry into the host cells (de Wit et al., 2016) . Interestingly, the envelope spike glycoprotein binds to its cellular receptor, angiotensin converting enzyme 2 (ACE2) for SARS-CoV (Li et al., 2003b) and SARS-CoV-2 (Figure 1) , dipeptidyl peptidase 4 for MERS-CoV (Raj et al., 2013) , and CD209L for SARS-CoV [26] . Although it was initially identified that SARS-CoV enters into cells by direct fusion of plasma membrane and virus (Simmons et al., 2004) . However, Belouzard et al. (2009) revealed that a vital proteolytic cleavage process takes place at SARS-CoV S protein at position (S2 ′ ) that facilitated the membrane fusion and infectivity of the virus. For membrane fusion, MERS-CoV also has evolved an aberrant 2 steps furin activation (Mille and Whittaker, 2014) . Other than membrane fusion, entry of SARS-CoV was also found to be mediated by the clathrin-independent and -dependent endocytosis (Wang et al., 2008; Kuba et al., 2010) . Following the entry of virus into the cells, RNA genome of SARS-CoV is released into the cytoplasm and is translated into 2 polyproteins and structural proteins, subsequently the viral genome starts to replicate (Perlman and Netland, 2009 ). The newly generated envelope glycoproteins are then inserted into the membrane of the endoplasmic reticulum or Golgi apparatus, and the It has been found that S protein is cleaved into S1 and S2 by a cell-derived protease, where S1 binds with ACE2 receptor, and S2 is activated by the host serine protease TMPRSS2 and results in a fusion with the cell membrane. Following the entry into the host cell, SARS-CoV-2 takeovers the host cell machinery to transcribe, replicate, and translate its RNA genome and structural proteins before being reassembled, encapsulated, and exocytosed from the host cell. Following exocytosis, SARS-CoV-2 is presented to host antigen presenting cells (APCs), which eventually leads to the generation of various cytokines including, TNF-α, CXCL-10, IL-1, and IL-6 (InvivoGen, 2020 

When the SARS-CoV-2 enters into the cells, its antigen will be presented to the antigen presentation cells (APCs) (Figure 1) , this process is crucial for the anti-viral immunity of the human body (Kumar et al., 2020) . Peptides of antigens are presented via major histocompatibility complex (MHC; or human leukocyte antigen (HLA) in humans) and then identified by virusspecific cytotoxic T lymphocytes. Therefore, the understanding of antigen presentation (AP) of the virus will provide a better understanding of the pathogenesis of nCOVID-19. However, not much information is available regarding this, thus we can obtain information from previous studies on MERS-CoV and SARS-CoV. AP of SARS-CoV-2 mostly relies on MHC I molecules (Liu et al., 2010) , nonetheless MHC II also plays roles in its presentation. Former studies revealed that many HLA polymorphisms associate with the susceptibility of SARS-CoV, for instance HLA-Cw * 0801 (Chen et al., 2006b) , HLA-B * 0703, HLA-DR B1 * 1202, and HLA-B * 4601 (Keicho et al., 2009) , while HLA-A * 0201, HLA-DR0301, and HLA-Cw1502 alleles are associated with the protection from SARS infection (Wang et al., 2011) . In case of MERS-CoV, it was observed that MHC II molecules (for example HLA-DQB1 * 02:0 and HLA-DRB1 * 11:01) were linked with the susceptibility to MERS-CoV infection (Hajeer et al., 2016) . Other than mannose-binding lectin gene polymorphisms linked with AP are associated with the risk of SARS-CoV infection (Tu et al., 2015) . Indeed, the aforementioned findings will give us an important idea regarding the mechanism, prevention, and treatment of nCOVID-19.

AP subsequently induces the human body's humoral and cellular immune responses, which are then facilitated via virus-specific B and T cells. Like other common acute viral infections, antibodies including IgG and IgM are produced against SARS-CoV virus.

It is estimated that at the end of week 12, SARS-specific IgM antibodies disappear. Whereas, SARS-specific IgG antibody can stay for a longer period, which is suggesting that IgG mainly has a protective function (Li et al., 2003a) . Furthermore, it was also found that SARS-specific IgG antibodies mainly are Nspecific and S-specific antibodies (de Wit et al., 2016) . Most of the studies have focused on cellular immune responses, as compared to the humoral immune responses in case of coronavirus. Recent findings have revealed that the levels of CD8 + and CD4 + T cells in the peripheral blood of nCOVID-19 individuals were significantly decreased, as confirmed by increased percentages of CD38 (CD8 39.4%) and HLA-DR (CD4 3.47%) double-positive fractions . Likewise, acute phase response in individuals with nCOVID-19 is linked with a marked decrease of CD8 + T and CD4 + T cells. Interestingly, it was found that although there is no presence of antigen, CD8 + , and CD4 + memory T cells can last for 4 years in individuals who have recovered from SARS-CoV and can perform IFNγ generation, delayed-type hypersensitivity response and T cell proliferation (Fan et al., 2009) . After 6 years of infection with SARS-CoV, specific T-cell memory responses to the SARS-CoV S peptide library can still be identified in 14 of 23 recovered SARS individuals (Tang et al., 2011) . In mouse models, specific CD8 + T cells also exhibited similar activity in the clearance of MERS-CoV (Zhao et al., 2014) . Indeed, these results might be useful in the rational designing of an effective vaccine against SARS-CoV-2.

Acute respiratory distress syndrome (ARDS) is considered as the major cause of nCOVID-19-related death. In the early stages of the epidemic, 6 out of the 41 admitted patients with confirmed nCOVID-19 died owing to ARDS . This ARDS is found to be the main immunopathological characteristic of SARS-CoV, MERS-CoV, and SARS-CoV-2 infections . Cytokine storm is the major characteristic of ARDS. This storm is a fatal uncontrolled systemic inflammatory response that takes place because of the high secretions of chemokines (i.e., C-X-C motif chemokine 10 Like SARS-CoV, MERS patients showed increased levels of CXCL-10, CXCL8, CCL5, IFN-α, and interleukin 6 (IL-6) in serum as compared to individuals with the mild to moderate disease (Min et al., 2016) . In the human body, a powerful cytokine storm will induce an aggressive attack by the immune system, which will lead to multiple organ failure and ARDS, and will ultimately result in death in severe novel coronavirus infection, as like MERS-CoV and SARS-CoV infection .

Various strategies are used by viruses including SARS-CoV and MERS-CoV to evade immune responses for their better survival in host cells. The pattern recognition receptors (PRRs) can identify the evolutionarily conserved microbial structures called pathogen-associated molecular patterns. Nonetheless, MERS-CoV and SARS-CoV can stimulate the generation of doublemembrane vesicles lacking PRRs and subsequently can replicate in these vesicles, thus evading the host detection of their doublestrand RNA (dsRNA) (Snijder et al., 2006) . IFN-I (IFN-β and IFN-α) plays a protective function on MERS-CoV and SARS-CoV infection, however the IFN-I mechanism is suppressed in infected mouse models (Channappanavar et al., 2016 (Channappanavar et al., , 2019 . Interestingly, by directly interacting with the dsRNA, MERS-CoV's accessory protein 4a might block the stimulation of IFN at the level of melanoma differentiation-associated protein 5 activation (Niemeyer et al., 2013) . IFN β promoter activation and transportation of IFN regulatory factor 3 to the nucleus can be inhibited by the ORF5, ORF4b, ORF4a, and membrane proteins of MERS-CoV (Yang et al., 2013) . SARS-CoV-2 can also affect the AP. In this regard, for instance, gene expression associated with AP is downregulated following MERS-CoV infection . Therefore, it is vital to terminate the immune evasion of coronavirus to develop specific and effective therapies.

Following an incubation period of around 5.2 days, the symptoms of SARS-CoV-2 infection appear . It takes around 6 to 41 days from the first appearance of the symptoms to death, along with a median of 14 days (Wang et al., 2020d) . However, the aforesaid durations depend on various factors including the patient's age and status of the immune system. This duration was found to be shorter for individuals older than 70-years old as compared to the individuals who are under the age of 70 (Wang et al., 2020d) . At the onset of the disease, the most commonly observed symptoms are cough, fatigue, and fever (Figure 2 ). In addition to this, various other symptoms including headache, lymphopenia, dyspnea, sputum production, diarrhea, and hemoptysis (Graham Carlos et al., 2020; Huang et al., 2020; Ren et al., 2020; Wang et al., 2020d) . Pneumonia has also been identified by computed tomography scan in nCOVID-19 patients, Unfortunately, various aberrant clinical features including ground-glass opacity (GGO), acute cardiac injury, and ARDS led to death . Occasionally, in subpleural areas of both lungs, the multiple peripheral GGOs were detected (Lei et al., 2020) and these triggered both localized and systemic immune responses, which collectively raised the level of inflammation. Unfortunately, treatment with interferon inhalation did not result in any clinical benefit, rather it aggravated the condition via facilitating pulmonary opacities (Lei et al., 2020) . Indeed, some of the symptoms of nCOVID-19 are similar to the earlier betacoronavirus including dyspnea, dry cough, fever, and bilateral GGOs . Nonetheless, there are some unique clinical manifestations of nCOVID-19 such as sore throat, sneezing, rhinorrhea (Lee et al., 2003; Assiri et al., 2013) . As revealed by chest radiographs following admission, in some cases it was observed that an infiltrate in lung's upper lobe is linked with growing dyspnea with hypoxemia (Phan et al., 2020) . Although nCOVID-19 exhibited digestive disorders like diarrhea, only a small proportion of SARS-CoV or MERS-CoV showed similar gastrointestinal symptoms. Thus, testing urine and fecal samples are important to eliminate a possible alternative mode of transmission (Lee et al., 2003; Assiri et al., 2013) . Henceforth, developing methods to detect different routes of transmission for example urine and fecal samples are immediately required to develop ways to suppress and/or minimize the transmission and also to discover therapies to treat nCOVID-19.

Recently, it has been observed that nCOVID-19 might predispose to both arterial and venous thromboembolic disease because of immobilization, hypoxia, inflammation, and diffuse intravascular coagulation Guan et al., 2020; Klok et al., 2020; Wang et al., 2020a; Zhou et al., 2020) . Furthermore, it was also revealed that respiratory failure in the disease is not only driven by the ARDS, rather microvascular thrombotic activities might also contribute in this regard (Grillet et al., 2020) . Therefore, Klok et al. (2020) have strongly suggested to administer pharmacological agents in a prophylactic manner to all the intensive care unit (ICU) nCOVID-19 patients.

For any given emergency department (ED) visiting patients with the symptoms of fever and respiratory diseases, healthcare workers must need to get a travel history in detail from that patient. If a patient shows flu-like symptoms and has a travel history to a country or area with confirmed nCOVID-19 cases or if the patient came into close contact with a confirmed nCOVID-19 patient in the last 14 days then the patient ought to be considered as a patient under investigation (PUI) (NPR, 2020) . It needs to be noted that here close contact means any individual who was within six feet of an individual with confirmed nCOVID-19 for an extended period. Furthermore, any individual who came into direct contact with the secretions of any nCOVID-19 patient will also be considered as a close contact.

Individuals who have traveled from high-risk countries or areas with confirmed nCOVID-19 cases and members of a family who are suffering from nCOVID-19 and not staying at home care or not maintaining isolation precautions are regarded as highrisk exposures. While medium risk exposures involve individuals who have traveled from low-risk countries or areas and family members are stringently maintaining appropriate home care and adhering with proper isolation precautions (WHO, 2020e). In contrast, low-risk exposures involve those individuals who were in the same indoor environment (for example in a waiting hall) for a longer period with nCOVID-19 patients but did not come into close contact.

Molecular assays of respiratory specimens are performed for diagnosis purposes usually at the regional referral laboratories designated by WHO (Kaiser Health News, 2020). For regional testing, the CDC started distributing nCOVID-19 test kits on February 7 (WHO, 2020a). nCOVID-19 test is getting more widely available day by day. For hospitals or institutions where nCOVID-19 test is not available, the only option is the testing by CDC. nCOVID-19 should be tested on an urgent basis for the PUI cases. An individual should be removed from PUI status only if that individual is fully evaluated clinically and has consulted with proper healthcare professionals.

The mode of SARS-CoV-2 transmission is still complex. Guidelines for nCOVID-19 prevention is mainly based on the previously developed guidelines for SARS and MERS and also on the intervening guidelines provided by CDC and WHO (CDC, 2020a,b; WHO, 2020a) . Before or upon arrival in ED, a PUI ought to be identified by the hospitals to protect the healthcare professionals and other patients. Prevention measures should involve maintaining hand and respiratory hygiene and also screening questions including travel history. Following a PUI identification, both local health department and hospital infection control ought to be immediately notified to avert further spread among healthcare professionals and other patients. A surgical mask must need to be given to any PUI and need to be isolated in a private room or if possible in a negative pressure room (WHO, 2020a).

As like SARS and MERS, nCOVID-19 is also found to spread through the airborne route. Therefore, surgical face masks might be beneficial to prevent sneeze and cough-related larger fluid droplets, however they are less likely to prevent small airborne contaminants (Yee et al., 2020) . In this regard, respirators containing air filters and adequate seal should be more beneficial (Tran et al., 2012; Smith et al., 2016) . In healthcare settings, right use of respirators and personal protective equipment and proper hand hygiene are likely to prevent transmission (Cowling et al., 2009; Radonovich et al., 2019; Yee et al., 2020) . If a patient requires hospital admission and there is no private or separate room for that patient, then that patient needs to be taken to an adequate facility containing institution. Isolated rooms and care provide would need to be customized in a way that reduces the exposure of healthcare providers to the patient. Indeed, along with an eye shield, all the healthcare providers must take measures to prevent contact with droplets and to maintain airborne precautions. Since the risk of transmission is much higher during the aerosol-generating procedures (such as intubation), in these cases the importance of PPE is enormous (Raboud et al., 2010; CDC, 2020a) . Still, it remains not known, regarding how long nCOVID-19 can stay airborne following a patient leaves the room. Respiratory protection is essential to enter into the vacated room.

Since still there is no specific drug to treat nCOVID-19, therefore the best approach will be taking preventative measures at a personal level including avoiding public transport, unnecessary travel, contact with nCOVID-19 suspected individuals, and so on.

Indeed, the significance of maintaining frequent and proper hand hygiene is paramount. Like other coronaviruses, SARS-CoV-2 has a lipid envelope, thus proper hand-washing with soap can break apart that lipid envelope and therefore can make it difficult or even impossible for the virus to infect humans. So far, this proper hand-washing is considered as the most effective preventative measure. In addition, duration of hand-washing with soap is also equally important. CDC has recommended that effective hand-washing should last at least for 20 s. In a study, Borchgrevink et al. (2013) showed that out of 3,749 individuals in a college town environment, only 5% of those individuals properly followed the hand-washing rules (i.e., washing, rubbing, and rinsing). This finding indicates that there is a poor understanding of the significance of proper handwashing among the general people. Therefore, awareness among people should be increased about the importance of frequent and proper hand-washing.

In order to form a physical barrier, the WHO has recommended the use of a face mask by those individuals who are showing respiratory symptoms (WHO, 2020b). However, healthy people are not required to use face masks. A typical surgical mask only provides one-way protection and can avert the spreading of droplets during coughing and sneezing to the surrounding areas. Healthcare professionals who are treating or in contact with a suspected or confirmed nCOVID-19 patient must need to wear a specialized respirator (for example N95 or its equivalent) to effectively prevent the droplets entry and thus can reduce the chance of acquiring the infection (Bae et al., 2020; WHO, 2020b) . Strict precautionary measures must need to be taken by the individuals during handling affected individual's body secretions including sputum, urine, or stools (Yeo et al., 2020) .

Remdesivir Out of all the investigational drugs, remdesivir (Figure 3) has appeared as the most effective and promising antiviral drug (Li and De Clercq, 2020) . This antiviral drug targets RNAdependent RNA polymerase (RdRp) of the virus while escaping proofreading via viral exoribonuclease, (Agostini et al., 2018) which can ultimately lead to early termination of viral RNA transcription as given in Figure 4 . Interestingly, remdesivir is a phosphoramidate prodrug and has a wide range of activities against numerous virus families, such as pneumoviridae, paramyxoviridae, filoviridae, and orthocoronavirinae (for example pathogenic MERS-CoV and SARS-CoV) (Sheahan et al., 2017; Martinez, 2020) .

In a COVID-19 mouse model, when remdesivir was administered prophylactically and as early therapeutic intervention, it significantly decreased the pulmonary viral load, which ultimately reduced the progression of the disease and significantly improved respiration (Sheahan et al., 2017) . In tissue culture models, Brown et al. revealed that remdesivir showed half-maximal effective concentration (EC 50 ) of 0.074 mM and 0.069 mM for MERS-CoV and SARS-CoV, successively . Furthermore, remdesivir (within the submicromolar EC50s) also effectively inhibited zoonotic CoV and human CoVs (HCoV-229E and HCoV-OC43) Ko et al., 2020) . Similar results were also observed when remdesivir was administered therapeutically (12 h post-inoculation) and prophylactically (24 h before prior inoculation) in MERS animal (rhesus macaque) model (de Wit et al., 2020) . Even 2 amino acid substitutions (V553L and F476L) in the non-structural protein 12 polymerase were found to show lower-level of resistance toward remdesivir (Agostini et al., 2018) .

In humans, pharmacokinetic data of remdesivir is not available. However, it has been revealed in rhesus monkeys that intravenous remdesivir administration at the dose of 10 mg/kg increased the intracellular concentration (over 10 mM) of active triphosphate form in peripheral blood mononuclear cells for a minimum of 24 h, which is indicating its clinical significance in nCOVID-19 treatment. Furthermore, human safety data of remdesivir are available online (Mulangu et al., 2019) . In USA, the first patient with confirmed nCOVID-19 was effectively treated with remdesivir for the advancement of pneumonia on 7th day of hospital admission in January, 2020 (Holshue et al., 2020) . Moreover, to assess its efficacy and safety to treat individuals with confirmed nCOVID-19, phase III clinical trials (ClinicalTrials.gov, 2020e) have been started in March 2020. In that study, individuals received 200 mg of remdesivir on first day, subsequently received 100 mg/day. Although remdesivir showed promising in vitro and clinical activity against coronavirus (Sheahan et al., 2017; Holshue et al., 2020) , recently it has been reported that there are some uncertainties because of its multiple adverse effects including hepatotoxicity, rectal hemorrhage (Jean et al., 2020b) .

In Japan, favipiravir (Figure 3) was primarily developed and approved as an anti-influenza drug (Shiraki and Daikoku, 2020; Wang et al., 2020b) . This antiviral drug has a wide range of activities against various RNA viruses including rhinovirus, respiratory syncytial virus (RSV), and influenza. Former studies revealed that favipiravir was successfully used to treat infections associated with rabies, Lassa virus, and Ebola virus (Shiraki and Daikoku, 2020) . Furthermore, favipiravir was also found to be effective to treat severe fever with thrombocytopenia syndrome (Shiraki and Daikoku, 2020) . Nevertheless, favipiravir was found to be ineffective against DNA viruses.

Favipiravir is a potent antiviral drug that selectively suppresses the RdRp of RNA viruses (Figure 4) Favipiravir is likely to produce resistant viruses, as compared to oseltamivir (Shiraki and Daikoku, 2020) . Indeed, this feature of favipiravir can be beneficial in the treatment of nCOVID-19. To treat influenza, favipiravir's recommended oral dose is 1,600 mg two times on first day, subsequently 600 mg twice/day from day 2 to 5, and 600 mg once/day on the sixth day. In recent times, initial findings of clinical trials have revealed that favipiravir exhibited significant activity in treating Chinese nCOVID-19 patients ( Table 2 ) (Xinhua News Agency). In China, favipiravir has been approved to treat nCOVID-19 in March 2020. Furthermore, in China, randomized controlled trials involving nCOVID-19 patients are also assessing the efficacy of favipiravir plus baloxavir marboxil (an antiviral drug) and favipiravir plus IFN-α (Arab-Zozani et al., 2020).

Ribavirin (Figure 3) is a RdRp inhibitor (Figure 4 ) used to treat various viral infections, for example, infections caused by RSV and hepatitis C virus (HCV) (Ogawa and Morisada, 2002) . It was revealed by in vitro studies that when ribavirin was administered at a concentration of 50 mg/mL, it showed effective antiviral activity against SARS-CoV (Chan et al., 2015) . Unfortunately, this antiviral drug was found to decrease the level of hemoglobin, therefore it can be detrimental for individuals with respiratory distress (Martinez, 2020) .

Umifenovir Umifenovir (Figure 3) is a potent antiviral agent that has a wide-range of activities against various viruses including HCV, influenza A and B viruses (Boriskin et al., 2008) . Umifenovir's mechanism slightly varies with different viruses. It has been revealed that umifenovir suppresses the fusion of the virus with the host cell membrane (Figure 4) , thus the subsequent viral entry into the host cell is inhibited (Boriskin et al., 2008) .

In a clinical trial, it has recently been observed that lopinavir/ritonavir (LPV/r, Figure 3 ) protease inhibitors that are mainly used in human immunodeficiency virus (HIV) treatment did not significantly improve the nCOVID-19 symptoms . Furthermore, in a different study, effect of umifenovir plus LPV/r was compared with the sole treatment with LPV/r to treat nCOVID-19 (Deng et al., 2020) . The findings of that study revealed that better effects were observed with the treatment of umifenovir plus LPV/r in comparison with the sole LPV/r treatment (Deng et al., 2020) . However, more studies are required to evaluate the incidence of resistance and efficacy. As coronavirus becomes activated on the membrane of the host cell, thus combination of LPV/r and umifenovir are likely to inhibit/prevent the viral entry into the host cell (Figure 4) . Besides, there is also a need regarding a better 

Chloroquine Chloroquine (Figure 3) is mainly used as an antimalarial drug. Furthermore, chloroquine is also used to treat various autoimmune disorders including rheumatoid arthritis and lupus erythematosus. In an animal model, it has recently been observed that chloroquine can also play a role as a potent antiviral drug against various viruses including influenza H5N1 (Yan et al., 2013) . Interestingly, chloroquine can prevent the viral fusion with the cell membrane of host cell by increasing endosomal pH (Figure 4) . Glycosylation of SARS-CoV's cellular receptors can also be interfered by chloroquine (Vincent et al., 2005; Wang et al., 2020b) . Even though findings from in vitro studies regarding chloroquine is auspicious (EC 90 = 6.90 mM, used nCOVID-19-infected Vero E6 cells), however use of chloroquine to treat nCOVID-19 infection is a completely off-label use. Furthermore, this drug is not strongly indicated due to some of its safety reasons including QT prolongation with ventricular dysrhythmia and adverse reactions on the renal, hepatic, and hematologic systems (Cortegiani et al., 2020) .

Hydroxychloroquine (a chloroquine derivative, Figure 3 ) is also mainly used as antimalarial and anti-inflammatory drugs (Sinha and Balayla, 2020) . It has been proposed that hydroxychloroquine controls cytokine storm (Figure 4) , which takes place in critically ill late phase nCOVID-19 patients (Yao et al., 2020) . As compared to chloroquine, hydroxychloroquine is more potent and their EC 50 values are 5.47 and 0.72, successively. In addition to this, hydroxychloroquine is less likely to interact with other drugs as compared to chloroquine. Moreover, in comparison with chloroquine phosphate, pharmacokinetic data confirmed that hydroxychloroquine is much more effective (5 days before) at inhibiting SARS-CoV-2 in vitro (Yao et al., 2020) . It has been declared on March 26, 2020 by Taiwan CDC that hydroxychloroquine has a significant role in the treatment of nCOVID-19 patients. However, treatment with hydroxychloroquine is contraindicated for the patients who are pregnant or breastfeeding, allergic to hydroxychloroquine, glucose-6-phosphatase deficient, and for individuals with prolonged QT interval in electrocardiograms and retinopathy (Gautret et al., 2020) .

Azithromycin Previously, azithromycin (Figure 3) showed excellent in vitro activity against Ebola virus (Madrid et al., 2016) . It was found that azithromycin was administered to individuals with viral infection, it prevented severe infections of respiratory tract in pre-school children (Bacharier et al., 2015) . In a recent study, when azithromycin was administered (i.e., 500 mg on first day, then 250 mg per day from day 2-5), it remarkably reinforced the hydroxychloroquine's efficacy (when 200 mg was administered 3 times/day for 10 days) to treat 20 severely ill nCOVID-19 patients (Figure 4) . The mean serum concentration of hydroxychloroquine was 0.46 ± 0.20 mg/mL. It is assumed that this excellent virus eliminating activity was achieved owing to the use of the aforesaid combination therapy (Gautret et al., 2020) . Therefore, use of azithromycin along with hydroxychloroquine can be an effective future alternative to remdesivir in nCOVID-19 treatment. However, in this regard, a possible complication related to prolonged QT interval should be taken into consideration.

Teicoplanin is a glycopeptide antibiotic and it has been revealed by Zhou et al. (Zhou et al., 2016 ) that teicoplanin exerted inhibitory activity (IC 50 as low as 330 nm) against replication-and transcription-competent virus-like particles. Studies confirmed that teicoplanin can suppress the entry of MERS and SARS envelope pseudotyped viruses Zhou et al., 2016) . In terms of its mechanism, teicoplanin can selectively suppress the effects of cathepsins B and L in host cell. These proteases are involved with cleaving the viral glycoprotein permitting exposure of the receptor-binding domain of its core genome and then release into the cytoplasm of host cells (Zhou et al., 2016; Baron et al., 2020) . Therefore, teicoplanin blocked the entry of Ebola virus in the late endosomal pathway. Also, the derivatives of teicoplanin including telavancin, dalbavancin, and oritavancin, were also found to block the entry of SARS, MERS, and Ebola viruses (Zhou et al., 2016) . Collectively, these findings suggest that teicoplanin and its derivatives might play a vital role in inhibiting the viruses that are dependent on cathepsin L ( Table 2) .

Ivermectin Ivermectin (Figure 3) is an antiparasitic agent and it has broadspectrum of activity (Caly et al., 2020) , Recent in vitro studies have revealed that this drug also has an antiviral effect against dengue and HIV viruses . It has been found that the preformed IMPα/β1 heterodimer is accountable for the transport of viral protein into the nucleus and ivermectin can dissociate this heterodimer. Since this transport of viral protein into the nucleus is important for the replication cycle and suppression of the host's antiviral response, thus targeting this viral protein transport might prove as a significant target in the development of therapeutic agents against RNA viruses (Caly et al., 2012; Yang et al., 2020a) . Following 48 h of nCOVID-19 infection, a recent in vivo study has been demonstrated that ivermectin can decrease the level of viral RNA (Figure 4 ) up to 5,000-times (Caly et al., 2020) . Since ivermectin has an established safety profile as an antiparasitic agent, thus now it is needed to establish a safe and effective dose of this drug in clinical trials to treat nCOVID-19 infection.

Nitazoxanide (Figure 3) is an effective antiparasitic and antiviral drug (Rossignol, 2016) . This drug has a broad-spectrum in vitro antiviral activity against a range of viruses including RSV, rotavirus, parainfluenza, influenza, and coronavirus (Rossignol, 2016) . In Vero-E6 cells, nitazoxanide exerted a potent in vitro antiviral activity against SARS CoV-2 (EC 50 = 2.12 µM, at 48 h) . Furthermore, this strong antiviral effect is in line with the observed EC 50 values for nitazoxanide (EC 50 = 0.92 µM) and tizoxanide (an active metabolite of nitazoxanide) (EC 50 = 0.83 µM) against MERS-CoV in LLC-MK2 cells (Rossignol, 2016) . In terms of its mechanism of action, it is believed that nitazoxanide has potent antiviral effect because of its ability to interfere with the host-regulated pathways associated with viral replication instead of the virus-specific pathways (Rossignol, 2016) . Therefore, studies were carried out to evaluate the ability of this drug to treat influenza and other related acute respiratory infections. In the phase IIb/III of a clinical trial, positive effects of nitazoxanide were observed in the management of influenza symptoms, where 600 mg of nitazoxanide was orally administered twice a day (Haffizulla et al., 2014) . Unfortunately, in phase II clinical trial it was observed that nitazoxanide neither alleviated the symptoms nor decrease the length of stay in hospitals of individuals infected with respiratory viruses (Gamiño-Arroyo et al., 2019). However, in vitro data regarding the activity of nitazoxanide against coronavirus is promising. Therefore, further studies are required to estimate its potential in nCOVID-19 treatment.

Baricitinib most commonly used in rheumatoid arthritis treatment. This drug is a reversible and selective inhibitor of Janus kinase 1 (JAK1) and JAK2. It has been found that these latter mentioned enzymes transduce intracellular signals for growth factors and cytokines associated with immune response, inflammation, and haematopoiesis. Moreover, this JAK inhibitor blocks the activities of AP2-associated with protein kinase 1, which ultimately prevents viral binding with the alveolar epithelium (Mayence and Vanden Eynde, 2019) . It has also been indicated that baricitinib might be used as an additional therapy for the COVID-19 treatment (Richardson et al., 2020) . In order to determine the safety and efficacy of sarilumab, hydroxychloroquine, lopinavir/ritonavir, and baricitinib to treat 1,000 hospitalized COVID-19 patients, a non-randomized phase II clinical study has recently been started (Scavone et al., 2020) . Other selective JAK inhibitors including ruxolitinib, fedratinib, and sunitinib might also be effective against COVID-19 in decreasing endocytosis of virus, inflammation, and levels of cytokines including IL-6 and IFN-γ (Bekerman et al., 2017; ClinicalTrials.gov, 2020f; Favalli et al., 2020; Scavone et al., 2020; Stebbing et al., 2020) .

Previously, convalescent plasma therapy was used as a terminal therapy to increase the survival rate of individuals with a range of viral infections including SARS, severe infection caused by Ebola virus, pandemic 2009 influenza A H1N1, H5N1 avian influenza Shen et al., 2020) . Convalescent plasma therapy can be effective because viremia can be suppressed due to the presence of plasma immunoglobulin antibodies in recovering patients. In a study, Shen et al. (2020) evaluated the effect of convalescent plasma therapy in 5 severely ill nCOVID-19 patients with ARDS. In that study, convalescent plasma was transfused in those patients with a novel coronavirus-specific antibody (neutralization titer >40 and binding titer > 1:1000). The used convalescent plasma of that study was obtained from five nCOVID-19-recovered individuals. The obtained convalescent plasma was then administered to the 5 patients (in between 10 and 22 days following admission) along with methylprednisolone and antiviral drugs. After convalescent plasma transfusion, clinical conditions of the patients were found to be improved, including decreased viral loads (patients became nCOVID-19 negative within 12 days), elevated level of SARS-CoV-2-specific enzyme-linked immunosorbent assay (ELISA), neutralizing antibody titers, normalized body temperature (within 3 days in four/five patients), improved ARDS (four patients at 12 days following transfusion), successful weaning from mechanical ventilation (three participating individuals within 2 weeks of therapy), increased partial pressure of oxygen/fraction of inspired oxygen, and reduced score in sequential organ failure assessment. Out of the 5 participants, 2 of them were in stable condition (at 37 days following transfusions), while 3 of them were discharged from the hospital (following 51, 53, and 55 days of staying in the hospital) (Shen et al., 2020) . Finally, the researchers summarized that although there were a small number of participants in this study, they suggested the therapy with convalescent plasma can be effective in the nCOVID-19 treatment (Shen et al., 2020) .

As a prophylactic measure and therapy, monoclonal and polyclonal antibodies (targeting hemagglutinin binding) have been recommended to treat various viral infections including influenza (Beigel et al., 2019) . The effectiveness of these antibodies against MERS-CoV largely encouraged the recent efforts to develop monoclonal and polyclonal antibodies against coronaviruses (Sheahan et al., 2017) . For instance, in a phase I trial, SAB-301 (a human polyclonal antibody) which was produced in transchromosomic cattle was found to be safe and better tolerated in healthy participants (Beigel et al., 2019) . In a study, Cockrell et al. (2016) revealed in mouse models that human monoclonal antibodies (mAbs)-based immunotherapy only mediated protection in the early stage of MERS (Martinez, 2020) . Many in vitro analyses showed that S protein of SARS-CoV is crucial to mediate the viral entry into the host cells. In addition to this, the cleavage and subsequent activation of the S protein of SARS-CoV via a host cell's protease is vital for the entry of the virus (Glowacka et al., 2011) . In cell cultures, it has been noticed that transmembrane serine protease 2 (TMPRSS2) is a vital protease of host cells that causes activation of S protein of SARS-CoV, therefore it was studied as an important target for antiviral drugs (Sheahan et al., 2017) . Previously, camostat mesylate (an inhibitor of serine protease) showed inhibitory activity against TMPRSS2 (Kawase et al., 2012) . Furthermore, K11777 (a cysteine protease inhibitor) exhibited significant inhibitory activity (at submicromolar range) against replication of MERS-CoV and SARS-CoV (Zhou et al., 2015) . Sarilumab is a human monoclonal antibody and 3 clinical trials are ongoing to assess the safety and efficacy of this antibody (alone or along with other standard therapies) in nearly 1,500 COVID-19 patients (ClinicalTrials.gov, 2020a,d,f; Scavone et al., 2020) .

Eculizumab (a monoclonal antibody) is approved to treat neuromyelitis spectrum disorders, refractory generalized myasthenia gravis, and atypical hemolytic uraemic syndrome. This monoclonal antibody inhibits the terminal portion of the inflammatory response-associated complement cascade. Although the function of the complement cascade in nCOVID-19 pathogenesis is not clear, numerous studies revealed that its suppression may effectively function as a therapeutic technique (Ip et al., 2005; Yuan et al., 2005; Gralinski et al., 2018) . Due to these findings, eculizumab will be tested in the SOLID-C19 clinical trial to treat individuals with severe ARDS and nCOVID-19 (ClinicalTrials.gov, 2020b). Currently, emapalumab (a monoclonal antibody) is being studied in an openlabel, randomized, phase II/III study to evaluate the safety and efficacy of this antibody in decreasing respiratory distress and hyper-inflammation in nCOVID-19 patients (ClinicalTrials.gov, 2020c) .

In China, stem cells are currently being studied as a treatment for nCOVID-19. Tocilizumab (a mAb) is an immunosuppressive agent and is used to treat rheumatoid arthritis (Kaneko, 2013) . This agent was designed to suppress the IL-6 binding with its receptors to alleviate cytokine storm syndrome. Tocilizumab is now being studied as a potential nCOVID-19 treatment (Jean et al., 2020b; Slater, 2020) .

In nCOVID-19 high-risk populations, traditional Chinese medicines were also regarded as a preventative measure, based on the traditional uses and anecdotal evidence of prevention of H1N1 pdm09 and SARS. Nonetheless, there is a lacking of clinical data regarding the effectiveness of these herbal medicines as an nCOVID-19 treatment (Cunningham et al., 2020; Luo et al., 2020) . In China, several traditional medicines were widely used during the nCOVID-19 epidemic and 6 of these herbal medicines include Lianqiao (Fructus forsythia), Jinyinhua (Lonicerae Japonicae Flos), Gancao (Glycyrrhizae Radix Et Rhizoma), Baizhu (Atractylodis Macrocephalae Rhizoma, rhizome of Atractylodes macrocephala Koidz), Fangfeng (Saposhnikoviae Radix, dried root from the perennial herb Saposhnikovia divaricate), and Huangqi (Astragali Radix, dried root of Astragalus membranaceus Bge. Var. mongholicus). Indeed, stringent clinical studies are required with a large number of participants to demonstrate the preventive role of these traditional Chinese medicines (Cunningham et al., 2020; Luo et al., 2020) .

The occurrence of co-infection can widely vary among the patients with confirmed nCOVID-19. Various reports suggest that several co-pathogens including viruses (such as rhinovirus, influenza, and HIV) and bacteria (for example Candida species, Mycoplasma pneumonia) can co-exist in these patients. Among them, influenza A virus was most commonly found to coexist (Jean et al., 2020b) . Furthermore, nCOVID-19 patients with pneumonia were found to be commonly treated by the coadministration of anti-influenza drugs and antibiotics (Jean et al., 2020b) . Therefore, careful selection of potential broadspectrum antibiotic(s) is required for the long-stay (over 6 days) hospitalized patients (Chou et al., 2019; Jean et al., 2020a) .

Mixed clinical findings were observed with the use of corticosteroids to treat SARS-CoV infections. Although various reports suggested that there was no significant contribution of corticosteroids in clinical outcomes (Stockman et al., 2006) . In contrast, it was suggested by a report that decreased mortality rate was observed due to the use of corticosteroids in critically ill patients (Chen et al., 2006a; Wu et al., 2020a) . Unfortunately, several reports suggested worse outcomes including longer time for viral clearance, or elevated composite endpoint of ICU admission or even death, owing to the use of corticosteroids (Auyeung et al., 2005) . In a cohort (n = 309), a longer time in viral clearance was observed in the corticosteroids-receiving MERS-CoV patients (Arabi et al., 2018) . Nevertheless, in the same study, it was observed that there was an insignificant decrease in 90-day mortality in corticosteroids-receiving patients. Recent reports suggested that there was a decreased rate of mortality in nCOVID-19 patients with ARDS due to the use of corticosteroids (Wu et al., 2020a) .

These findings suggest that use of corticosteroids resulted in inconsistent outcomes. However, corticosteroids might be beneficial for patients with cytokine-linked lung injury and those who might rapidly develop progressive pneumonia . Indeed, healthcare professionals need to carefully assess the risk and benefit ratio of corticosteroid use for each patient. This necessity to assess risk and benefit of corticosteroid use in individual patients and its careful dose consideration has been demonstrated in diagnosis and treatment guidelines from China's National Health Commission. As per that guideline, glucocorticoid (equivalent to methylprednisolone 1-2 mg/kg per day for three-five days or less) may be considered based on chest imaging and respiratory distress. Large-dose of glucocorticoids can suppress the immune system, this can result in delayed SARS-CoV-2 clearance (McCreary and Pogue, 2020) . Recently, Chinese Thoracic Society recommended a lower dose of methylprednisolone (≤ 0.5-1 mg/kg per day) for a maximum of 7 days in selected patients, prior to treatment these selected patients should be carefully assessed for potential risks and benefits . More clinical studies are immediately required to elucidate the function of corticosteroids in nCOVID-19.

In a study, Yang et al. (2020b) mentioned that diabetes and cerebrovascular diseases were the commonly observed comorbidities in the non-survivors of nCOVID-19 in ICUs. Furthermore, Guan et al. (2020) also observed similar results in their study and these nCOVID-19 patients received angiotensin II receptor blockers (ARBs) or ACE inhibitors. Indeed, SARS-CoV-2 and SARS-CoV can bind with the ACE2 receptors on the epithelial cells of lung, kidney, and intestine (Fang et al., 2020) . Therefore, when ARDS is not present, ARB or ACE inhibitors can be administered to nCOVID-19 patients. Increased activity of ACE2 was found to be linked with decreased severity of ARDS among individuals with RSV-caused lower respiratory tract infection (Wösten-van Asperen et al., 2013) . Interestingly, Fedson (2016) revealed in their study that statins mainly target host response to infection, instead of the virus itself. These researchers also indicated that combination therapy with statins and ARB may induce the reversal of homeostatic processes, which will allow the self-recovery of individuals (Fedson et al., 2020) .

There is an argument regarding the usage of non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen since it can increase the ACE2 receptors (Day, 2020) . If the severely ill nCOVID-19 individuals suffer from fever, acetaminophen can be a good option to control body temperature as compared to other NSAIDs (Therapeutics Initiative, 2020). Tang et al. (2020) confirmed that anticoagulant therapy by heparin (an anticoagulant) specially with low molecular weight heparin improved the prognosis in severely ill patients with nCOVID-19. Furthermore, 28-day mortality of heparin receivers was found to be lower as compared to the non-users among individuals with sepsis-stimulated coagulopathy scores 4 or Ddimer > 6-times the upper limit of normal .

In human body, vitamin A plays various important functions including protecting mucosal and epithelium integrity, mediating growth and development, and proper maintenance of vision (Huang et al., 2018) . Vitamin A is also essential for enhancing immune response and maintaining regulatory action in both humoral and cellular immune responses (Huang et al., 2018) . In case of infants, supplementation with vitamin A was found to ameliorate antibody response following several vaccines including anti-rabies (Siddiqui et al., 2001) and measles vaccination (Huang et al., 2018) . Moreover, an improved immune response to influenza virus vaccination has also been reported in children (2-8 years) who had a deficiency of vitamin A and D at baseline, following supplementation with vitamin A and D (Patel et al., 2019) .

Vitamin D has a significant contribution in modifying both adaptive and innate immune responses (Aranow, 2011) . It has been revealed by epidemiological studies that there is a link between deficiency of vitamin D and elevated susceptibility to acute viral respiratory infections (Monlezun et al., 2015) . It has also been suggested that vitamin D significantly modulates the innate immune responses against various viral respiratory infections including RSV, parainfluenza 1 and 2, and influenza A and B (Zdrenghea et al., 2017) . Indeed, studies have revealed that there is a strong relationship between vitamin D deficiency and elevated risk of both lower and upper respiratory tract infections (Jolliffe et al., 2013) . Nonetheless, conflicting and heterogeneity in dosage regimens and baseline vitamin D conditions in study populations were observed in randomized controlled trials (RCTs) (Jolliffe et al., 2013) . In a study, Aglipay et al. (2017) observed no significant difference between the action of high-dose (2000 IU per day) vs. standard-dose (400 IU per day) vitamin D supplementation on viral upper respiratory tract infections (Aglipay et al., 2017) . Nevertheless, only one-third of the study subjects received vitamin D at doses below 30 ng/ml. Vitamin D increased the plasma level of TGFβ without ameliorating antibody generation in a RCT on the effect of vitamin D administration on influenza vaccine response in deficient elderly person (Goncalves-Mendes et al., 2019) . In addition to this, it was also indicated in the latter mentioned RCT that vitamin D administration perhaps directed the polarization of lymphocyte toward a tolerogenic immune response (Goncalves-Mendes et al., 2019) . In a different RCT, monthly administration of high-dose of vitamin D (100,000 IU/month) decreased the occurrence of acute respiratory infections in older long-term care residents as compared to a standard dose group (12,000 IU/month) (Ginde et al., 2017) . Therefore, it is quite clear that the effect of vitamin D on antiviral immunity against respiratory infections is dependent on an individual's vitamin D status. Moreover, it has been confirmed that vitamin D supplementation is also useful in case of other viral infections, for instance, vitamin D addition to conventional Peg-α-2b/ribavirin therapy for treatment-naive individuals with chronic HCV genotype 1 infection considerably ameliorated the viral response (Abu-Mouch et al., 2011) , and similar action was also seen in individuals with HCV genotype 2-3 (Nimer and Mouch, 2012) .

Vitamin E possesses strong antioxidant property and it can modify host immune responses [14] . The deficiency of this vitamin can lead to impairment of both cellular and humoral immune responses (Moriguchi and Muraga, 2000) . Some studies revealed that administration of vitamin E may exert harmful activities in case of infectious disease. Vitamin E increased the risk of pneumonia among 50-69 years old adult smokers (Hemilä and Kaprio, 2008) . Similarly, vitamin E supplementation (200 IU/day) did not significantly reduce the respiratory tract infections in elderly nursing facility residents (Meydani et al., 2004) . Nevertheless, in a small pilot RCT, positive activities of vitamin E were seen in the treatment of chronic hepatitis B, where vitamin E administration markedly normalized the liver enzymes and HBV-DNA negativization (Andreone et al., 2001) . Similarly, in a RCT, vitamin E supplementation increased anti-HBe seroconversion and virological response in the pediatric population (Fiorino et al., 2017) .

Vitamin C plays a significant role as an enzymatic cofactor in numerous physiological reactions including immune potentiation, collagen synthesis, and hormone generation . In mouse models, it was revealed that vitamin C plays important role in the antiviral immune responses against the influenza A virus (H3N2) via the elevated generation of IFN-α/β, particularly at the early stages of infection . Nonetheless, no significant benefit has been observed in using mega-dose of vitamin C as a prophylactic measure to lower the incidence of common cold caused by viral infections (Hemilä and Chalker, 2013) .

Zinc (an essential trace element) contributes significantly in the growth, development, and maintenance of immune responses (Prasad, 2013; Read et al., 2019) . The deficiency of zinc is linked with an enhanced susceptibility toward infectious diseases, for example, viral infections. An individual's zinc status is a vital factor that can affect the immune response against viral infections. Indeed, zinc-deficient individuals are at greater risk of developing infections including HCV or HIV (Read et al., 2019) . Acevedo-Murillo et al. (2019) reported that there was a noticeable clinical improvement in the 103 children (1 month−5 years) with pneumonia in the zinc-receiving group as compared to placebo (Acevedo-Murillo et al., 2019) . The researchers also confirmed that there was a rise in the cytokine response in Th1 pattern (INF-γ and IL-2) only in the zinc-receiving group, along with Th2 cytokines (IL-10 and IL-4) being increased or remained elevated in both groups. Following stem cell transplantation, oral administration of a high dose of zinc (150 mg/day) increased thymic activity and output of new CD4 + naive T cells, which eventually helped in the prevention of Torque Teno virus reactivation (Iovino et al., 2018) . Nonetheless, Provinciali et al. (1998) summarized that prolonged administration of zinc (400 mg/day) or zinc plus arginine (4 d/day) in the elderly (age 64-100 years) people restored zinc concentrations in plasma, which was ineffective in stimulating or improving the antibody response or number of CD3, CD4, or CD8 lymphocytes following influenza vaccination.

Selenium (a trace element) also exerts a range of important functions including antioxidant effects, various pleiotropic activities, and anti-inflammatory effects (Rayman, 2012) . Selenium deficiency is found to be linked with cognitive impairment, poor immune response, and elevated risk of mortality, whereas an increased level of selenium or treatment with selenium has exhibited antiviral actions (Rayman, 2012) . Broome et al. (2004) assessed whether an increased selenium administration (50-100 µg/day) ameliorated immune response in adults with a borderline concentration of selenium (Broome et al., 2004) . Treatment with selenium elevated the plasma selenium levels, and also increased the activities of cytosolic glutathione peroxidase and lymphocyte phospholipid. Furthermore, selenium also increased the cellular immune responses (elevated level of IFN-γ and other cytokines), along with an increased level of T-helper cells and earlier peak Tcell proliferation. Nonetheless, it was observed that humoral immune responses were not affected (Broome et al., 2004) . Moreover, selenium treatment in participants also induced rapid poliovirus clearance.

Copper (another essential trace element) has a significant contribution in the differentiation and development of immune cells (Li et al., 2019) . It has also been confirmed that copper exerted in vitro antiviral effects. Intracellular copper was found to regulate the life cycle of influenza virus (Rupp et al., 2017) , while thujaplicin-copper chelates inhibited the replication of human influenza viruses (Miyamoto et al., 1998) . In a study, Turnlund et al. (2004) determined the effects of chronic administration of copper on immune response, oxidative stress, and indices of copper status. These researchers observed that when copper was administered at a dose of 7.8 mg/day, copper significantly increased the level of superoxide dismutase, benzylamine oxidase, and plasma ceruloplasmin activity as compared to 1.6 mg/day dose, which further suggesting an enhancement in antioxidant status. Nonetheless, increased copper administration (7.8 mg/day) markedly decreased the proportion of antibody titer, serum IL-2R, and circulating neutrophils against the Beijing strain of influenza (Turnlund et al., 2004) .

Magnesium (an essential mineral) has a significant contribution in regulating immune response via significantly affecting the T helper-B cell adherence, macrophage response to lymphokines, Immunoglobulin M (IgM) lymphocyte binding, adherence with immune cells, antibody-dependent cytolysis, and immunoglobulin synthesis (Liang et al., 2012) . It has also been reported in in vivo and in-vitro studies that magnesium may have a contribution in the immune function against viral infections (Chaigne-Delalande et al., 2013) .

Still now there is no specific antiviral drug to treat nCOVID-19, but some of the investigational drugs were found to be useful. Various drugs are being analyzed in vitro studies or clinical trials. Although ribavirin is a potent antiviral drug, its clinical effects are not clear and its side effects ought to be carefully considered. On the other hand, chloroquine has been studied in 15 interventional studies. Furthermore, in the Chinese Clinical Trial Registry, the derivatives of chloroquine were prospectively registered; and more studies are required to evaluate their antiviral effects and to estimate the recommended dose in nCOVID-19 patients . Along with antiviral drugs, glucocorticoids ought to be utilized carefully and in a timely manner in nCOVID-19 patients. In addition to this, extracorporeal support need to be considered under strict contraindications and indications, otherwise, there will be numerous additional complications and also a waste of resources .

In order to manage the current nCOVID-19 outbreak, extensive measures are needed to be taken to lower the personto-person transmission of the virus. In addition to this, special efforts and attention are required to reduce or protect the susceptible populations such as elderly people, health care providers, and children. More studies are also essential to understand the mechanisms related to nCOVID-19 pathogenesis. This better understanding will help the development of specific and effective therapies against SARS-CoV-2. Since the respiratory tract is mainly affected by SARS-CoV-2, thus special consideration is required to deliver the drug into the respiratory tract. More studies in animals and clinical trials on drug repositioning can also be considered to identify potential drugs to treat nCOVID-19.

Still there is no available specific drug or vaccine to treat nCOVID-19, thus effective preventative measures are recommended. Specific drugs are urgently required to inhibit the entry of the virus and subsequent replication to overcome this outbreak. Currently, as mentioned in this article, multiple investigational drugs and clinical trials are ongoing. The discovery of new drugs will ultimately enable us to better control this outbreak. Furthermore, in silico studies can also be considered to faster the drug development process. Finally, sharing findings or data will be effective to fight against nCOVID-19 globally.

MK and MU conceived the original idea and designed the outlines of the study and prepared the figures for the manuscript. MK wrote the initial draft of the manuscript. MU revised and improved the draft. MH, JA, MA, GA, SB, MB-J, MA-D, and LA participated in the literature review of the manuscript. All authors have read and approved the final manuscript.

Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients

Zinc supplementation promotes a Th1 response and improves clinical symptoms in fewer hours in children with pneumonia younger than 5 years old

Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review

Effect of high-dose vs standard-dose wintertime Vitamin D supplementation on viral upper respiratory tract infections in young healthy children

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial

Corticosteroid therapy for critically ill patients with middle east respiratory syndrome

Favipiravir for treating novel coronavirus (COVID-19) patients: protocol for a systematic review and meta-analysis of controlled trials. medRxiv

Vitamin D and the immune system

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study

Early Administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses a randomized clinical trial

Effectiveness of surgical and cotton masks in blocking SARS-CoV-2: a controlled comparison in 4 patients

The influence of temperature on mortality and its lag effect: a study in four Chinese cities with different latitudes

Teicoplanin: an alternative drug for the treatment of COVID-19?

Advances in respiratory virus therapeutics -a meeting report from the 6th isirv antiviral group conference

Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel

Hand washing practices in a college town environment

Arbidol: a broadspectrum antiviral compound that blocks viral fusion

An increase in selenium intake improves immune function and poliovirus handling in adults with marginal selenium status

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

Influence of meteorological factors and air pollution on the outbreak of severe acute respiratory syndrome

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?

Human immunopathogenesis of severe acute respiratory syndrome (SARS)

A Trial of lopinavir-ritonavir in adults hospitalized with severe covid-19

Cases in the U.S. Available online at

Infection Control Guidance for Healthcare Professionals about Coronavirus (COVID-19)

Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D

Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset

The emerging novel middle east respiratory syndrome coronavirus: the "knowns" and "unknowns

The effects of temperature and relative humidity on the viability of the SARS coronavirus

Dysregulated type i interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoVinfected mice

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Convalescent plasma as a potential therapy for COVID-19

Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003

Recommendations and guidelines for the treatment of pneumonia in Taiwan

Cohort Multiple Randomized Controlled Trials Openlabel of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients -Sarilumab Trial -CORIMUNO-19 -SARI

Eculizumab (Soliris) in Covid-19 Infected Patients

Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients

A mouse model for MERS coronavirus-induced acute respiratory distress syndrome

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Facemasks and hand hygiene to prevent influenza transmission in households: a cluster randomized trial

Air pollution and case fatality of SARS in the people's republic of China: an ecologic study

Treatment of COVID-19: Old tricks for new challenges

The impact of cold on the respiratory tract and its consequences to respiratory health

Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

SARS and MERS: recent insights into emerging coronaviruses

Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study

Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

COVID-19 infection and rheumatoid arthritis: faraway, so close!

Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of, 019 Coronavirus Disease

Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola

Hiding in plain sight: an approach to treating patients with severe covid-19 infection

Coronaviruses: an overview of their replication and pathogenesis

Vitamin E for the treatment of children with hepatitis B e antigen-positive chronic hepatitis: a systematic review and meta-analysis

Global Fujifilm accelerates production of its influenza antiviral drug "Avigan R Tablet" for COVID-19

Human coronavirus: hostpathogen interaction

Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness

A systematic review of asymptomatic infections with COVID-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

High-dose monthly vitamin D for prevention of acute respiratory infection in older long-term care residents: a randomized clinical trial

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

Impact of vitamin D supplementation on influenza vaccine response and immune functions in deficient elderly persons: a randomized placebo-controlled trial

Novel wuhan (2019-NCoV) coronavirus

Return of the coronavirus: 2019-nCoV

Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis

Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography

Clinical characteristics of coronavirus disease 2019 in China

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial

Heat-related mortality: a review and exploration of heterogeneity

Association of human leukocyte antigen class II alleles with severe middle east respiratory syndrome-coronavirus infection

Vitamin C for preventing and treating the common cold

Vitamin E supplementation and pneumonia risk in males who initiated smoking at an early age: effect modification by body weight and dietary vitamin C

First case of 2019 novel coronavirus in the united states

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Role of Vitamin A in the immune system

Spotlight on COVID-19: Infection

High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation

Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection

Decline in temperature and humidity increases the occurrence of influenza in cold climate

Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia

Treatment options for COVID-19: the reality and challenges

Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies

CDC Coronavirus Testing Decision Likely To Haunt Nation For Months To Come

Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents

Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry

Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the vietnamese population

Vitamin C is an essential factor on the anti-viral immune responses through the production of interferon-α/β at the initial stage of influenza a virus (H3N2) infection

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Arguments in favour of remdesivir for treating SARS-CoV-2 infections

Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters

Low ambient humidity impairs barrier function and innate resistance against influenza infection

Host immune response and immunobiology of human SARS-CoV-2 infection

Quasispecies theory and the behavior of RNA viruses

A major outbreak of severe acute respiratory syndrome in Hong Kong

CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology

The role of copper homeostasis at the host-pathogen axis: from bacteria to fungi

Profile of specific antibodies to the SARS-associated coronavirus

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Scientific research progress of COVID-19/ SARS-CoV-2 in the first five months

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Magnesium affects the cytokine secretion of CD4+ T lymphocytes in acute asthma

Environmental factors on the SARS epidemic: air temperature, passage of time and multiplicative effect of hospital infection

Novel immunodominant peptide presentation strategy: a featured HLA-A * 2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein

Time-varying transmission dynamics of novel coronavirus pneumonia in China

Roles of humidity and temperature in shaping influenza seasonality

Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle

Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs

Effects of temperature variation and humidity on the death of COVID-19 in Wuhan

Evaluation of ebola virus inhibitors for drug repurposing

Compounds with therapeutic potential against novel respiratory 2019 coronavirus

Baricitinib: a 2018 novel FDAapproved small molecule inhibiting janus kinases

Coronavirus disease 2019 treatment: a review of early and emerging options

MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape

Vitamin E and respiratory tract infections in elderly nursing home residents: a randomized controlled trial

Host cell entry of middle east respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein

Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity

Thujaplicin-copper chelates inhibit replication of human influenza viruses

Vitamin D status and acute respiratory infection: cross sectional results from the United States national health and nutrition examination survey

Vitamin E and immunity

A randomized, controlled trial of ebola virus disease therapeutics

Novel coronavirus: current understanding of clinical features, diagnosis, pathogenesis, and treatment options

Middle east respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist

Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients

Coronavirus Has Now Spread To All Regions Of Mainland China

Novel mode of action of ribavirin (Rebetol R ), a drug for the treatment of chronic hepatitis C: inducting the mutation of RNA viruses

Effects of temperature, humidity, and diurnal temperature range on influenza incidence in a temperate region

Baseline serum vitamin A and D levels determine benefit of oral vitamin A&D supplements to humoral immune responses following pediatric influenza vaccination

Severe acute respiratory syndrome

Coronaviruses post-SARS: update on replication and pathogenesis

Importation and human-to-human transmission of a novel coronavirus in vietnam

Genetic diversity and evolution of SARS-CoV-2

Novel coronavirus: from discovery to clinical diagnostics

Discovery of human zinc deficiency: its impact on human health and disease

Effect of zinc or zinc plus arginine supplementation on antibody titre and lymphocyte subsets after influenza vaccination in elderly subjects: a randomized controlled trial

Outcome reporting from protocols of clinical trials of coronavirus disease 2019 (COVID-19): a review. medRxiv

Risk factors for SARS transmission from patients requiring intubation: a multicentre investigation in Toronto

N95 respirators vs medical masks for preventing influenza among health care personnel: a randomized clinical trial

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

Coronavirus infections: epidemiological, clinical and immunological features and hypotheses

Selenium and human health

The role of zinc in antiviral immunity

Identification of a novel coronavirus causing severe pneumonia in human

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Nitazoxanide, a new drug candidate for the treatment of middle east respiratory syndrome coronavirus

Host cell copper transporters CTR1 and ATP7A are important for influenza A virus replication

The neighbor-joining method: a new method for reconstructing phylogenetic trees

Current pharmacological treatments for COVID-19: what's next?

Interim Clinical Guidance for Patients Suspected of Confirmed With COVID-19

On the use of corticosteroids for 2019-nCoV pneumonia

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Treatment of 5 critically III patients with COVID-19 with convalescent plasma

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

The role of vitamin A in enhancing humoral immunity produced by antirabies vaccine

Characterization of severe acute respiratory syndromeassociated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry

Hydroxychloroquine and covid-19

FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia. Cancer Net

Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis

Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex

COVID-19: combining antiviral and anti-inflammatory treatments

SARS: Systematic review of treatment effects

Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Acetaminophen vs. NSAIDs During COVID-19 Pandemic

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review

Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection

Long-term high copper intake: effects on indexes of copper status, antioxidant status, and immune function in young men

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan

SARS coronavirus entry into host cells through a novel clathrin-and caveolaeindependent endocytic pathway

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Temperature significant change COVID-19 transmission in 429 cities

Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection

Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan

Teicoplanin inhibits Ebola pseudovirus infection in cell culture

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Coronavirus Disease (COVID-19) Technical Guidance: Laboratory Testing for 2019-nCoV in Humans

Advice on the Use of Masks in the Context of COVID-19

Landscape Analysis of Therapeutics as 21st

Novel Coronavirus -China

Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)

The mercurial nature of neutrophils: still an enigma in ARDS?

Imbalance between pulmonary angiotensinconverting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

A new coronavirus associated with human respiratory disease in China

Favipiravir Shows Good Clinical Efficacy in Treating COVID-19: Official

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model

The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of middle east respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Novel coronavirus 2019 (COVID-19): emergence and implications for emergency care

Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible?

Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan

Influence of FcgammaRIIA and MBL polymorphisms on severe acute respiratory syndrome

Vitamin D modulation of innate immune responses to respiratory viral infections

Controversial treatments: an updated understanding of the coronavirus disease 2019

The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes

Rapid generation of a mouse model for Middle East respiratory syndrome

Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)

Protease inhibitors targeting coronavirus and filovirus entry

Coronaviruses-drug discovery and therapeutic options

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2020 Kabir, Uddin, Hossain, Abdulhakim, Alam, Ashraf, Bungau, Bin-Jumah, Abdel-Daim and Aleya. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

